According to the most recent 13F filing that Invitae Co. made with the Securities and Exchange Commission, during the third quarter of 2018, Strs Ohio decreased its holdings of Invitae Co. (NYSE: NVTA) by 15.9%. (SEC). The company finished the period with 224,200 shares of the stock held by the medical research company after selling 42,500 shares of stock during the period in question. At the close of the most recent financial quarter, Strs Ohio held an interest in Invitae with a value of $551,000; this represented 0.10 percent of the total company.
Throughout the past few months, several other significant investors have made modifications to the holdings that they have in NVTA. During the second quarter, Mackenzie Financial Corporation achieved a 25.1% increase in the proportion of Invitae stock it owned. After making an additional 2,795 stock purchases during the relevant period, Mackenzie Financial Corp. now has 13,948 shares of the medical research company’s stock worth $34,000. These shares were acquired during the period in question. In the first three months of 2018, Private Advisor Group LLC made a 9.7% increase in the amount of Invitae stock it owned, bringing its total ownership percentage to 100%. Private Advisor Group LLC now holds 32,282 shares of the medical research company’s stock following the acquisition of an additional 2,845 shares during the most recent period. The value of Private Advisor Group LLC’s current stock holdings is $258,000. During the second quarter, FMR LLC achieved a 2.9% increase in the proportion of Invitae shares it owned. FMR LLC now has a total of 112,499 stock in the medical research business, which is worth a combined total of $275,000 after purchasing an additional 3,175 shares during the time in question. During the second quarter, Capital Impact Advisors LLC increased the amount of Invitae stock owned by 4.3%, bringing the total to 100%. Capital Impact Advisors LLC has a total of 77,820 shares of the medical research company’s stock after making a new purchase of 3,229 shares during the time frame in question. The stock is currently valued at $190,000. This is the final and most important point to make, as it relates to the fact that AdvisorNet Financial Inc. increased its holdings in Invitae by 61.0% during the third quarter. After making purchases totaling 3,788 shares throughout the most recent period, AdvisorNet Financial Inc. now holds a total of 10,000 shares of the publicly traded stock of the medical research company, which has a current market value of $25,000. Institutional investors and hedge funds are the current owners of 76.79% of the company’s shares.
In related news about this matter, Director Sean E. George conducted a transaction on Friday, December 16th, in which he sold 44,816 shares. This event took place on the day in question. The total value of the stock that changed hands was $91,424.64, and the price received per share, on average, was $2.04. Following the completion of the transaction, the director now owns a total of 743,840 shares in the company, each of which has an approximate value of $1,517,433.60. On the Securities and Exchange Commission website, one can find a copy of the legal file that disclosed the transaction. This file contains the details of the transaction (SEC). 1.10 company insiders own a percent of the total shares currently outstanding.
Recent analyst reports have focused most frequently on NVTA’s performance. William Blair reaffirmed its recommendation for “market performs” for the shares of Invitae in a research note published on November 8th. Cowen stated that they had increased their price target for Invitae to $2.80 in a research note made public on November 15th and published by Cowen. SVB Leerink raised their price objective on Invitae from $2.50 to $3.00 and categorized the company as “market perform” in a research note published on November 9th. Last but not least, in a research report released on Friday, November 18th, StockNews.com changed its rating for Invitae from “hold” to “sell.” Four financial analysts have recommended selling the stock, while nine others have suggested that investors keep the stock in their portfolios. According to Bloomberg, the current average rating for Invitae is “Hold,” and the market’s consensus price objective is $8.04 per share. This information was obtained from a survey of analysts.
When trading started on Thursday morning, a share of NVTA was $2.58. This was the previous day’s high. The company has a price-to-earnings ratio of -0.1